Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.12 (
PKG
)
2,515
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prolidase
[E.C. 3.4.13.9], a member of the matrix metalloproteinase (MMP) family, is a manganese-dependent cytosolic exopeptidase that cleaves imidodipeptides containing C-terminal proline or hydroxyproline. It plays an important role in collagen metabolism, matrix remodeling and cell growth. Nitric oxide (NO), a versatile signaling molecule, regulates many processes including collagen synthesis and matrix remodeling and, thereby, may modulate angiogenesis, tumor invasiveness, and metastasis. Thus, we considered that
prolidase
may be an important target of NO regulation. In our study, SIN I and DETA/NO were used as NO donors. Both donors increased
prolidase
activity in a time-dependent and dose-dependent manner.
Prolidase
activity increased not only with NO donors but also with endogenous NO in cells transfected with iNOS. The effect of iNOS was abolished by treatment with S-methylisothiourea (SMT), a selective inhibitor of iNOS. However, with either exogenous or endogenous sources of NO, the increase in
prolidase
activity was not accompanied by increased
prolidase
expression. Therefore, we suspected phosphorylation of
prolidase
as a potential mechanism regulating enzyme activation. We observed increased serine/threonine phosphorylation on
prolidase
protein in cells treated with NO donors and in cells transfected with iNOS. To determinate the pathways that may mediate
prolidase
induction by NO, we first used 8-Br-cGMP, a cGMP agonist, and found that 8-Br-cGMP strongly and rapidly stimulated
prolidase
activity accompanied by increased phosphorylation. Rp-8-Br-pCPT-cGMP, an inhibitor of cGMP, reduced NO donor-stimulated
prolidase
activity to control levels. To test whether the MAPK pathway is involved in this NO-dependent activation, we used an ERK1/2 inhibitor and found that it had no effect on
prolidase
activity increased by NO donors. These results demonstrate that NO stimulates
prolidase
activity by increasing serine/threonine phosphorylation through
PKG
-cGMP pathway, but independent of MAPK and suggest an interaction between inflammatory signaling pathways and regulation of the terminal step of matrix degradation.
...
PMID:Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. 1616 38